Search Results - "Beckwith, Kyle A"

Tetraspanins as therapeutic targets in hematological malignancy: a concise review by Beckwith, Kyle A, Byrd, John C, Muthusamy, Natarajan

“…Tetraspanins belong to a family of transmembrane proteins which play a major role in the organization of the plasma membrane. While all immune cells express…”
Get full text

Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease by Hertlein, Erin, Beckwith, Kyle A, Lozanski, Gerard, Chen, Timothy L, Towns, William H, Johnson, Amy J, Lehman, Amy, Ruppert, Amy S, Bolon, Brad, Andritsos, Leslie, Lozanski, Arletta, Rassenti, Laura, Zhao, Weiqiang, Jarvinen, Tiina M, Senter, Leigha, Croce, Carlo M, Symer, David E, de la Chapelle, Albert, Heerema, Nyla A, Byrd, John C

“…Studies of chronic lymphocytic leukemia (CLL) have yielded substantial progress, however a lack of immortalized cell lines representative of the primary…”
Get full text

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia by Fraietta, Joseph A., Beckwith, Kyle A., Patel, Prachi R., Ruella, Marco, Zheng, Zhaohui, Barrett, David M., Lacey, Simon F., Melenhorst, Jan Joseph, McGettigan, Shannon E., Cook, Danielle R., Zhang, Changfeng, Xu, Jun, Do, Priscilla, Hulitt, Jessica, Kudchodkar, Sagar B., Cogdill, Alexandria P., Gill, Saar, Porter, David L., Woyach, Jennifer A., Long, Meixiao, Johnson, Amy J., Maddocks, Kami, Muthusamy, Natarajan, Levine, Bruce L., June, Carl H., Byrd, John C., Maus, Marcela V.

“…Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly promising but requires robust T-cell expansion and engraftment. A T-cell defect in chronic…”
Get full text

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes by Dubovsky, Jason A., Beckwith, Kyle A., Natarajan, Gayathri, Woyach, Jennifer A., Jaglowski, Samantha, Zhong, Yiming, Hessler, Joshua D., Liu, Ta-Ming, Chang, Betty Y., Larkin, Karilyn M., Stefanovski, Matthew R., Chappell, Danielle L., Frissora, Frank W., Smith, Lisa L., Smucker, Kelly A., Flynn, Joseph M., Jones, Jeffrey A., Andritsos, Leslie A., Maddocks, Kami, Lehman, Amy M., Furman, Richard, Sharman, Jeff, Mishra, Anjali, Caligiuri, Michael A., Satoskar, Abhay R., Buggy, Joseph J., Muthusamy, Natarajan, Johnson, Amy J., Byrd, John C.

“…Given its critical role in T-cell signaling, interleukin-2–inducible kinase (ITK) is an appealing therapeutic target that can contribute to the pathogenesis of…”
Get full text

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia by Hing, Zachary A., Mantel, Rose, Beckwith, Kyle A., Guinn, Daphne, Williams, Erich, Smith, Lisa L., Williams, Katie, Johnson, Amy J., Lehman, Amy M., Byrd, John C., Woyach, Jennifer A., Lapalombella, Rosa

“…Despite the therapeutic efficacy of ibrutinib in chronic lymphocytic leukemia (CLL), complete responses are infrequent, and acquired resistance to Bruton…”
Get full text

Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells by Do, Priscilla, Beckwith, Kyle A, Cheney, Carolyn, Tran, Minh, Beaver, Larry, Griffin, Brittany G, Mo, Xiaokui, Liu, Yang, Lapalombella, Rosa, Hertlein, Erin, Muthusamy, Natarajan, Byrd, John C

“…The clinical benefit of CTLA-4 blockade on T cells is known, yet the impact of its expression on cancer cells remains unaddressed. We define an…”
Get full text

Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib by Kittai, Adam S., Huang, Ying, Beckwith, Kyle A., Bhat, Seema A., Bond, David A., Byrd, John C., Goldstein, Daniel, Grever, Michael R., Miller, Cecelia, Rogers, Kerry A., Yano, Max, Woyach, Jennifer A.

“…Chronic lymphocytic leukemia (CLL) transformation to aggressive lymphoma, known as Richter's Transformation (RT), has a dismal prognosis. There are limited…”
Get full text

Toll-Like Receptors and Dectin-1, a C-Type Lectin Receptor, Trigger Divergent Functions in CNS Macrophages by Gensel, John C, Wang, Yan, Guan, Zhen, Beckwith, Kyle A, Braun, Kaitlyn J, Wei, Ping, McTigue, Dana M, Popovich, Phillip G

“…Spinal cord injury (SCI) activates macrophages, endowing them with both reparative and pathological functions. The mechanisms responsible for these divergent…”
Get full text

Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib by Kittai, Adam S, Huang, Ying, Keiter, Ashleigh, Beckwith, Kyle A, Goldstein, Daniel, Bhat, Seema A, Bond, David A., Byrd, John C., Grever, Michael R, Rogers, Kerry A, Woyach, Jennifer A.

“…Background: Aggressive lymphoma arising in the setting of chronic lymphocytic leukemia (CLL), known as Richter's syndrome (RS), is associated with poor…”
Get full text

Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib by Goldstein, Daniel, Beckwith, Kyle A., Miller, Cecelia, Huang, Ying, Abruzzo, Lynne V., Bhat, Seema A, Bond, David A., Byrd, John C., Grever, Michael R., Heerema, Nyla A, Rogers, Kerry A., Ruppert, Amy S., Woyach, Jennifer A., Kittai, Adam S.

“…Introduction: Our group and others have previously shown that the presence of complex karyotype (>/= 3 cytogenetic abnormalities) is an important prognostic…”
Get full text

Leukemic B Cell CTLA-4 Suppresses Co-stimulation of T cells by Do, Priscilla, Beckwith, Kyle A., Cheney, Carolyn, Tran, Minh, Beaver, Larry, Griffin, Brittany G., Mo, Xiaokui, Liu, Yang, Lapalombella, Rosa, Hertlein, Erin, Muthusamy, Natarajan, Byrd, John C.

“…Clinical benefit of CTLA-4 blockade on T cells is known, yet the impact of its expression on cancer cells remains unaddressed. We define an immunosuppressive…”
Get full text

Leukemic cell expressed CTLA-4 suppresses T cells via down-modulation of CD80 by trans-endocytosis by Do, Priscilla, Beckwith, Kyle A, Beaver, Larry, Griffin, Brittany G, Mo, Xiaokui, Liu, Yang, Jones, Jeffrey A, Hertlein, Erin, Muthusamy, Natarajan, Byrd, John C

“…Despite clinical utility in targeting the immune checkpoint, Cytotoxic T Lymphocyte Antigen 4 (CTLA-4), on T cells, its function on non-T cells remains…”
Get full text

The Role of Tetraspanin CD37 in B-Cell Malignancy by Beckwith, Kyle A., Williams, Erich I., Wright, Mark D., van Spriel, Annemiek B., Byrd, John C., Muthusamy, Natarajan

“…Members of the tetraspanin superfamily of transmembrane proteins have roles in a variety of processes including cellular adhesion, migration, activation,…”
Get full text

Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis by Do, Priscilla, Beckwith, Kyle A., Beaver, Larry, Griffin, Brittany G., Mo, Xiaokui, Jones, Jeffrey, Hertlein, Erin K., Muthusamy, Natarajan, Byrd, John C.

“…The function of CTLA-4 on non-T cells is largely ignored and currently ill defined despite rapidly growing interest in targeting this immune checkpoint protein…”
Get full text

Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells by Zhong, Y, El-Gamal, D, Dubovsky, J A, Beckwith, K A, Harrington, B K, Williams, K E, Goettl, V M, Jha, S, Mo, X, Jones, J A, Flynn, J M, Maddocks, K J, Andritsos, L A, McCauley, D, Shacham, S, Kauffman, M, Byrd, J C, Lapalombella, R

Get full text

Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients by Long, Meixiao, Beckwith, Kyle A., Maddocks, Kami J., Cheney, Carolyn, Woyach, Jennifer A., Johnson, Amy J., Muthusamy, Natarajan, Byrd, John C.

“…Introduction: Chronic lymphocytic leukemia (CLL) has multiple mechanisms of active immune suppression including expansion of T-regulatory cells which increases…”
Get full text

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma by Stephens, Deborah M, Beckwith, Kyle A., Do, Priscilla, Cheney, Carolyn, Mo, Xiaokui, Larkin, Karilyn, Jones, Jeffrey, Awan, Farrukh T., Grosmaire, Laura, Jones, Randy, DiPaolo, Julie, Tannheimer, Stacey, Heider, Karl-Heinz, Byrd, John C., Muthusamy, Natarajan

“…Background Targeting new antigens in chronic lymphocytic leukemia (CLL) and lymphoma may increase flexibility in the clinic and help circumvent resistance. The…”
Get full text

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia by Stephens, Deborah M, Beckwith, Kyle A, Cheney, Carolyn, Mo, Xiaokui, Flynn, Joseph M, Jones, Jeffrey A., Maddocks, Kami J., Heider, Karl-Heinz, Muthusamy, Natarajan, Byrd, John C.

“…Novel chronic lymphocytic leukemia (CLL) therapies target phosphoinositide 3-kinase (PI3K; idelalisib) and Bruton’s tyrosine kinase (BTK; ibrutinib). Despite…”
Get full text

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism by Long, Meixiao, Beckwith, Kyle A., Do, Priscilla, Bethany, Mundy L, Gordon, Gordon, Lehman, Amy M., Maddocks, Kami J., Cheney, Carolyn, Jones, Jeffrey, Andritsos, Leslie A., Awan, Farrukh T., Fraietta, Joseph A., June, Carl H, Maus, Marcela V., Woyach, Jennifer A., Caligiuri, Michael A., Johnson, Amy J., Muthusamy, Natarajan, Byrd, John C.

“…Background: Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) that induces durable remissions in chronic lymphocytic leukemia (CLL). In…”
Get full text

The CD37-targeted antibody–drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model by Beckwith, K A, Frissora, F W, Stefanovski, M R, Towns, W H, Cheney, C, Mo, X, Deckert, J, Croce, C M, Flynn, J M, Andritsos, L A, Jones, J A, Maddocks, K J, Lozanski, G, Byrd, J C, Muthusamy, N

“…Therapeutic regimens for chronic lymphocytic leukemia (CLL) have increasingly utilized monoclonal antibodies since the chimeric anti-CD20 antibody rituximab…”
Get full text